BRPI0417744B8 - método para produzir um conjugado imunogênico, e,conjugado imunogênico - Google Patents
método para produzir um conjugado imunogênico, e,conjugado imunogênicoInfo
- Publication number
- BRPI0417744B8 BRPI0417744B8 BRPI0417744A BRPI0417744A BRPI0417744B8 BR PI0417744 B8 BRPI0417744 B8 BR PI0417744B8 BR PI0417744 A BRPI0417744 A BR PI0417744A BR PI0417744 A BRPI0417744 A BR PI0417744A BR PI0417744 B8 BRPI0417744 B8 BR PI0417744B8
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic
- conjugate
- producing
- immunogenic conjugate
- protein
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
método para produzir um conjugado imunogênico, e, conjugado imunogênico a presente invenção é dirigida a métodos de produzir conjugados de imunógenos de peptídeo com moléculas portadoras de proteína/polipeptídeo, que são úteis como imunógenos, em que os imunógenos de peptídeo são conjugados com portadores de proteína via grupos funcionais ativados de resíduos de aminoácido do portador ou da molécula ligadora opcionalmente fixada e em que quaisquer grupos funcionais reativos não-conjugados nos resíduos de aminoácido são inativados via capeamento, assim retendo a funcionalidade imunológica da molécula portadora, porém reduzindo a propensão para reações indesejáveis, que poderiam tornar o conjugado menos seguro ou eficaz. além disso, a invenção também refere-se a tais produtos imunogênicos e composições imunogênicas contendo tais produtos imunogênicos, produzidos por tais métodos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53048003P | 2003-12-17 | 2003-12-17 | |
| US60/530480 | 2003-12-17 | ||
| PCT/US2004/042701 WO2005058940A2 (en) | 2003-12-17 | 2004-12-17 | Immunogenic peptide carrier conjugates and methods of producing same |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0417744A BRPI0417744A (pt) | 2007-04-10 |
| BRPI0417744A8 BRPI0417744A8 (pt) | 2017-08-08 |
| BRPI0417744B1 BRPI0417744B1 (pt) | 2020-11-03 |
| BRPI0417744B8 true BRPI0417744B8 (pt) | 2021-05-25 |
Family
ID=34700142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417744A BRPI0417744B8 (pt) | 2003-12-17 | 2004-12-17 | método para produzir um conjugado imunogênico, e,conjugado imunogênico |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20070134762A1 (pt) |
| EP (1) | EP1701968B1 (pt) |
| JP (1) | JP4764830B2 (pt) |
| KR (1) | KR101157694B1 (pt) |
| CN (1) | CN1984676A (pt) |
| AR (1) | AR046960A1 (pt) |
| AU (1) | AU2004299501B2 (pt) |
| BR (1) | BRPI0417744B8 (pt) |
| CA (1) | CA2549132C (pt) |
| CR (1) | CR8444A (pt) |
| DK (1) | DK1701968T3 (pt) |
| EA (2) | EA010060B1 (pt) |
| EC (1) | ECSP066655A (pt) |
| ES (1) | ES2546175T3 (pt) |
| HU (1) | HUE026000T2 (pt) |
| IL (1) | IL176006A0 (pt) |
| MY (1) | MY146566A (pt) |
| NO (1) | NO340432B1 (pt) |
| NZ (1) | NZ548352A (pt) |
| PL (1) | PL1701968T3 (pt) |
| PT (1) | PT1701968E (pt) |
| SG (2) | SG182163A1 (pt) |
| SI (1) | SI1701968T1 (pt) |
| TW (1) | TWI355390B (pt) |
| UA (1) | UA93854C2 (pt) |
| WO (1) | WO2005058940A2 (pt) |
| ZA (1) | ZA200604957B (pt) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2004069182A2 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
| TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| EA009559B1 (ru) * | 2003-12-17 | 2008-02-28 | Элан Фармасьютикелз, Инк. | КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| EP1828251B1 (en) * | 2004-10-05 | 2012-09-26 | Janssen Alzheimer Immunotherapy | Methods and compositions for improving recombinant protein production |
| CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| KR102611449B1 (ko) | 2005-04-08 | 2023-12-06 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| EP1879613B1 (en) * | 2005-05-05 | 2011-11-30 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| KR101247836B1 (ko) * | 2005-06-17 | 2013-03-28 | 와이어쓰 엘엘씨 | 항 ａ 베타 항체의 정제 방법 |
| AU2006312013B2 (en) | 2005-11-02 | 2012-10-04 | Duke University | Concurrent chemotherapy and immunotherapy |
| DK1954718T3 (en) | 2005-11-30 | 2014-12-15 | Abbvie Inc | Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, |
| CN101506236B (zh) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
| CN101384279B (zh) * | 2006-02-24 | 2012-02-22 | 奇斯药制品公司 | 抗淀粉样蛋白免疫原性组合物、方法和用途 |
| WO2007112079A2 (en) * | 2006-03-24 | 2007-10-04 | Duke University | Multivalent immunogen |
| WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| MX2009001133A (es) * | 2006-08-01 | 2009-02-11 | Scripps Research Inst | Vacunas y metodos para controlar adiposidad. |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2231180B1 (en) * | 2008-01-16 | 2016-08-17 | Ben-gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
| EP2145898A1 (en) | 2008-07-15 | 2010-01-20 | CHIESI FARMACEUTICI S.p.A. | Anti-amyloid immunogenic compositions, methods and uses |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| RU2531234C2 (ru) | 2009-06-22 | 2014-10-20 | ВАЙЕТ ЭлЭлСи | КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus |
| CN102481352A (zh) | 2009-06-22 | 2012-05-30 | 惠氏有限责任公司 | 金黄色葡萄球菌抗原的免疫原性组合物 |
| CN101671689B (zh) * | 2009-07-29 | 2013-05-01 | 中国农业科学院上海兽医研究所 | 含日本血吸虫基因的重组表达载体及其应用 |
| CA2768346A1 (en) * | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| JP6091214B2 (ja) * | 2009-11-16 | 2017-03-08 | ザ ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレイティド | ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| US20130116423A1 (en) | 2010-04-23 | 2013-05-09 | A. Stewart Campbell | Synthetic Oligosaccharides for Staphylococcus Vaccine |
| US8716469B2 (en) | 2010-04-27 | 2014-05-06 | Ancora Pharmaceuticals, Inc. | Synthetic oligosaccharides for Moraxella vaccine |
| WO2011149778A1 (en) | 2010-05-26 | 2011-12-01 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for neisseria meningitis vaccine |
| ES2648882T3 (es) | 2010-07-19 | 2018-01-08 | Yeda Research And Development Co. Ltd. | Péptidos basados en el dominio de transmembrana de un receptor tipo toll (TLR) para el tratamiento de enfermedades mediadas por TLR |
| JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
| WO2012073111A2 (en) * | 2010-11-29 | 2012-06-07 | Akershus Universitetssykehus | Methods and compositions for monitoring phagocytic activity |
| CN102526724B (zh) * | 2011-01-14 | 2015-07-22 | 四川大学 | 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途 |
| ES2728653T3 (es) * | 2011-05-18 | 2019-10-28 | Matrivax Inc | Composiciones vacunales con una matriz proteica que incluye policationes |
| KR101281098B1 (ko) * | 2011-06-30 | 2013-07-02 | 주식회사 녹십자 | Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도 |
| EP2766384B1 (en) * | 2011-10-10 | 2016-11-23 | Yeda Research and Development Co. Ltd. | Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response |
| RU2495048C1 (ru) * | 2012-04-18 | 2013-10-10 | Андрей Валентинович Исаев | Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов |
| CN102731659B (zh) * | 2012-06-07 | 2014-05-07 | 北京交通大学 | 一种6×His-C99重组蛋白及其制备方法和应用 |
| JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 共有結合している抗原−抗体結合体 |
| CN103497927B (zh) * | 2013-10-21 | 2016-02-10 | 深圳大学 | 表达分泌金葡菌肠毒素蛋白的重组bcg活菌菌株、活菌疫苗及其构建方法和应用 |
| MX373856B (es) | 2014-01-03 | 2020-03-25 | Hoffmann La Roche | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| CN111228509A (zh) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用 |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3998077A1 (en) * | 2014-05-07 | 2022-05-18 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN104059142B (zh) * | 2014-07-03 | 2016-11-23 | 江南大学 | 一种用于制备沙门氏菌交叉型抗体的免疫原的合成方法 |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| EP3233896A1 (fr) * | 2014-12-18 | 2017-10-25 | Biomérieux | Composé synthétique biépitopique |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| CN107648618B (zh) * | 2017-09-27 | 2020-05-08 | 国家纳米科学中心 | 一种药物递送体系及其制备方法与应用 |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| CN110018253A (zh) * | 2019-04-15 | 2019-07-16 | 艾美卫信生物药业（浙江）有限公司 | 一种生物制品中游离蛋白含量的高效液相测定方法 |
| CL2019003847A1 (es) * | 2019-12-26 | 2021-08-06 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv |
| CN111499724A (zh) * | 2020-04-15 | 2020-08-07 | 上海领潮生物新材料有限公司 | 一种s-腺苷同型半胱氨酸-鸡卵白蛋白偶联物的制备方法 |
| CN111896737B (zh) * | 2020-08-03 | 2023-07-07 | 北京望尔生物技术有限公司 | 一种蛇形菌素人工抗原在酶联免疫试剂盒中的应用 |
| AU2021409394A1 (en) | 2020-12-21 | 2023-07-27 | Cornell University | Peptide-linked drug delivery system |
| WO2022249107A2 (en) * | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024025397A1 (ko) * | 2022-07-29 | 2024-02-01 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
| CN115583992A (zh) * | 2022-11-02 | 2023-01-10 | 江南大学 | 一种氧化还原响应的载体蛋白及其在制备疫苗中的应用 |
| CN116059401B (zh) * | 2023-02-22 | 2025-04-29 | 东南大学 | 一种双功能纳米探针及其制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5126131A (en) * | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
| US5089603A (en) * | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| US5192540A (en) | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| ES2109945T3 (es) | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| ATE148889T1 (de) | 1991-09-18 | 1997-02-15 | Affymax Tech Nv | Verfahren zur synthese der verschiedenen sammlungen von oligomeren |
| JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ，ミヒャエル | 油除去装置を備えたエンジン |
| EP1958646A1 (en) * | 1992-02-11 | 2008-08-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| IL107166A (en) | 1992-10-01 | 2000-10-31 | Univ Columbia | Complex combinatorial chemical libraries encoded with tags |
| PT616034E (pt) | 1993-03-05 | 2005-02-28 | Wyeth Corp | Plasmideo para a producao de proteina crm e toxina da difteria |
| EP0735893B1 (en) | 1993-09-14 | 2008-11-26 | Pharmexa Inc. | Pan dr-binding peptides for enhancement of the immune response |
| EP0726906A4 (en) | 1993-11-02 | 1998-10-07 | Affymax Tech Nv | THE SYNTHESIS AND EXAMINATION OF MOLECULAR DIVERSITY |
| US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| AU691296B2 (en) | 1994-05-06 | 1998-05-14 | Pharmacopeia Drug Discovery, Inc. | Combinatorial dihydrobenzopyran library |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| IL115933A0 (en) | 1995-11-09 | 1996-01-31 | Oramir Semiconductor Ltd | Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls |
| CA2235226A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| CN1868545A (zh) | 1996-10-23 | 2006-11-29 | 宾夕法尼亚州立大学托管会 | 改良疫苗 |
| US6962984B2 (en) * | 1996-12-05 | 2005-11-08 | Nihon University | IgA nephropathy-related DNA |
| EP0848011B1 (en) | 1996-12-16 | 2001-03-21 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Method of coupling polysaccharides to proteins |
| US5877220A (en) * | 1997-03-06 | 1999-03-02 | Genta, Incorporated | Amide-based oligomeric cationic lipids |
| US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| JP2002504380A (ja) | 1998-02-27 | 2002-02-12 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | ワクチン、免疫療法剤およびそれらの使用法 |
| CA2264970A1 (en) * | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| US6645503B1 (en) * | 1998-03-10 | 2003-11-11 | Wyeth Holdings Corporation | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
| MXPA01003228A (es) | 1998-09-30 | 2003-06-24 | American Cyanamid Co | Holotoxina de colera mutante como un coadyuvante. |
| JP2002537354A (ja) * | 1999-02-25 | 2002-11-05 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原 |
| US6945135B1 (en) * | 1999-09-09 | 2005-09-20 | L. H. Thomson Company, Inc. | Bicycle stem for enlarged handlebar portions and associated methods |
| US20030190322A1 (en) * | 2000-03-31 | 2003-10-09 | Peter Kaastrup | Immunostimulating properties of a fragment of tgf-beta |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| AU2002322380B2 (en) | 2001-06-07 | 2006-11-02 | Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences | Mutant forms of cholera holotoxin as an adjuvant |
| WO2002098368A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| US20030135035A1 (en) * | 2001-08-09 | 2003-07-17 | Mark Shannon | Human ZZAP1 protein |
| WO2003045128A2 (en) * | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
| US9296795B2 (en) * | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| EA009559B1 (ru) * | 2003-12-17 | 2008-02-28 | Элан Фармасьютикелз, Инк. | КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
-
2004
- 2004-12-17 US US10/583,464 patent/US20070134762A1/en not_active Abandoned
- 2004-12-17 AR ARP040104757A patent/AR046960A1/es active IP Right Grant
- 2004-12-17 EP EP04814839.9A patent/EP1701968B1/en not_active Expired - Lifetime
- 2004-12-17 SI SI200432252T patent/SI1701968T1/sl unknown
- 2004-12-17 HU HUE04814839A patent/HUE026000T2/en unknown
- 2004-12-17 PT PT48148399T patent/PT1701968E/pt unknown
- 2004-12-17 DK DK04814839.9T patent/DK1701968T3/da active
- 2004-12-17 PL PL04814839T patent/PL1701968T3/pl unknown
- 2004-12-17 EA EA200601169A patent/EA010060B1/ru active IP Right Revival
- 2004-12-17 EA EA200800300A patent/EA012984B1/ru unknown
- 2004-12-17 ES ES04814839.9T patent/ES2546175T3/es not_active Expired - Lifetime
- 2004-12-17 TW TW093139525A patent/TWI355390B/zh not_active IP Right Cessation
- 2004-12-17 NZ NZ548352A patent/NZ548352A/en not_active IP Right Cessation
- 2004-12-17 WO PCT/US2004/042701 patent/WO2005058940A2/en active Application Filing
- 2004-12-17 CN CNA2004800378024A patent/CN1984676A/zh active Pending
- 2004-12-17 UA UAA200608018A patent/UA93854C2/ru unknown
- 2004-12-17 SG SG2012041109A patent/SG182163A1/en unknown
- 2004-12-17 SG SG200809163-9A patent/SG149013A1/en unknown
- 2004-12-17 CA CA2549132A patent/CA2549132C/en not_active Expired - Lifetime
- 2004-12-17 AU AU2004299501A patent/AU2004299501B2/en not_active Ceased
- 2004-12-17 KR KR1020067014273A patent/KR101157694B1/ko not_active Expired - Fee Related
- 2004-12-17 JP JP2006545540A patent/JP4764830B2/ja not_active Expired - Fee Related
- 2004-12-17 MY MYPI20045203A patent/MY146566A/en unknown
- 2004-12-17 BR BRPI0417744A patent/BRPI0417744B8/pt not_active IP Right Cessation
-
2006
- 2006-05-30 IL IL176006A patent/IL176006A0/en active IP Right Grant
- 2006-06-08 CR CR8444A patent/CR8444A/es unknown
- 2006-06-09 NO NO20062687A patent/NO340432B1/no not_active IP Right Cessation
- 2006-06-15 ZA ZA2006/04957A patent/ZA200604957B/en unknown
- 2006-06-16 EC EC2006006655A patent/ECSP066655A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417744B8 (pt) | método para produzir um conjugado imunogênico, e,conjugado imunogênico | |
| BRPI0417689A8 (pt) | Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado | |
| Gauthier et al. | Arginine-specific modification of proteins with polyethylene glycol | |
| BRPI0612654B8 (pt) | método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína | |
| PE20091388A1 (es) | Moleculas y metodos para modular el componente de complemento | |
| BR0111191A (pt) | Moléculas mutantes de ctla4 solúveis e seus usos | |
| BRPI0508935A (pt) | agonistas de receptor seletivo y4 para intervenções terapêuticas | |
| Jbara et al. | Oligonucleotide bioconjugation with bifunctional palladium reagents | |
| WO2014057436A3 (en) | Anticancer conjugate | |
| EP0467700A2 (en) | Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties | |
| DE69224988D1 (de) | Aminosäurederivat und bromacetyl-modifizierte peptide | |
| CA2047031A1 (en) | Peptide-polysaccharide-protein conjugate vaccines | |
| BR0113439A (pt) | Processo para a manufatura de um imunógeno para vacina, derivado de maleimida de peptìdeo de ige, uso do mesmo, conjugado adequado para uso em uma vacina e composição de vacina | |
| EP4129344A1 (en) | Immune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same | |
| TH115317A (th) | Ab อิมมูโนจีนิกเพปไทด์แคริเออร์คอนจูเกตและวิธีการผลิตสารเดียวกันนี้ | |
| Kragol et al. | Synthesis of a disulfide-linked octameric peptide construct carrying three different antigenic determinants | |
| Deng et al. | Multifunctional Cys labeling-directed N-terminus-selective stapling strategy development | |
| Taniguchi et al. | 2P-025 Direct observation of GroEL-substrate complexes by high-speed atomic force microscopy (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan) | |
| Nicola et al. | A novel glycoconjugation method and unexpected photo-induced site-selective protein cleavage reaction | |
| Kaita et al. | 2P-026 Transduction of fluctuations along internal mechanical network in molecular machines (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan) | |
| Nakamura et al. | 2P-024 Molecular interactions of CD28 cytoplasmic domains with Grb2 and Gads using their SH3-deficient mutants (Protein: Structure & Function, The 47th Annual Meeting of the Biophysical Society of Japan) | |
| BRPI0416913A (pt) | peptìdeo de eritropoietina, método de fabricação da eritropoietina peguilada, uso do peptìdeo e formulação farmacêutica | |
| BR122019025343B8 (pt) | molécula de ácido nucleico, vetor e método para preparação de uma molécula de anticorpo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: WYETH LLC (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: WYETH LLC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: WYETH LLC (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |